ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
P/E ratio for ORIC Pharmaceuticals, Inc. (ORIC)
P/E ratio as of 2023: -4.70
According to ORIC Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.70. At the end of 2022 the company had a P/E ratio of -2.55.
P/E ratio history for ORIC Pharmaceuticals, Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.70 |
| 2022 | -2.55 |
| 2021 | -7.18 |
| 2020 | -7.64 |
| 2019 | -30.24 |
| 2018 | -23.09 |
| 2017 | -34.98 |